UW Medicine was one of the clinical trial sites for aducanumab, a drug just approved by the FDA that may slow the progression of Alzheimer’s disease. The drug, created by Biogen, is not a cure for the disease and there’s some debate about the extent of its benefits.
Charles Bernick, clinical trials director of UW Medicine’s Memory and Brain Wellness Center, says this FDA approval is a significant step in the field of Alzheimer’s research.
